# Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients

> **NCT02161822** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 60 (actual)

## Conditions studied

- Adenocarcinoma of Rectum

## Interventions

- **DRUG:** simvastatin

## Key facts

- **NCT ID:** NCT02161822
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161822, "Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02161822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*